The currently available oral immunotherapy for peanut allergy in toddlers carries the risk of treatment-related anaphylaxis and gastrointestinal events. These drawbacks call for alternative routes with better safety profiles. In this regard, a study investigated daily epicutaneous immunotherapy via a peanut patch in children aged 1-3 years (n=382) with peanut allergy . The children were randomized to receive the peanut or placebo patch applied to the interscapular area for 12 months. The patch contained 250 ฮผg of lyophilized peanut protein.
The first patch was applied for three hours under medical supervision, and the duration for the at-home application was adjusted over four weeks. After a year of treatment, more children with peanut patches showed peanut desensitization compared to the placebo group (67.0% vs. 33.5%). They exhibited safe ingestion of approximately 3 to 4 peanuts ( โฅโฆ
